Please ensure Javascript is enabled for purposes of website accessibility

Abiomed's Revenue Growth Accelerates to 40%

By Brian Feroldi - May 4, 2018 at 9:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The medical device company knocks the cover off the ball in its fiscal fourth-quarter results.

Abiomed (ABMD 2.69%), a medical device company focused on cardiovascular disease, reported its fiscal fourth-quarter and full-year earnings results on May 3. The Impella heart-pump maker reported sales growth of 40%, which marks its second consecutive quarter of accelerating top-line growth. When combined with margin improvements, earnings per share jumped by an impressive 142%. 

Abiomed's fiscal fourth quarter: The raw numbers


Q4 2018

Q4 2017

Year-Over-Year Change


$174.4 million

$124.7 million


GAAP net income

$36.8 million

$14.9 million


Earnings per share




Data source: Abiomed. 

Close up picture of surgeon wearing glasses

Image source: Getty Images.

What happened with Abiomed this quarter?

  • Sales of the company's family of Impella heart pumps grew 42% on a worldwide basis to $168.3 million. The strong top-line growth was driven by 35% sales growth in the U.S. and 107% growth in international markets. 
  • Operating margin jumped by 400 basis points year over year to 27.3%.
  • Management credited the triple-digit earnings growth to higher revenue, favorable operating leverage, and a lower tax rate.

Zooming out to the full year, here's how Abiomed performed in fiscal 2018:

  • Revenue jumped 33% to $594 million.
  • Gross margin declined slightly to 83.4%.
  • Operating margin increased by 630 basis points to 26.5%.
  • Net income more than doubled to $112 million, or $2.45 per share.

What management had to say

CEO Michael Minogue was quite pleased that his company was able to cap off fiscal 2018 on such a high note:

Abiomed delivered another record quarter and fiscal year. I am proud of our Patients First execution and operational discipline from research to manufacturing to customer support. We earned multiple global regulatory approvals in the U.S., Germany, and Japan on new products, new indications and reimbursement.

Looking forward

Abiomed's management team expects that the good times will continue into fiscal 2019. Specifically, here's the guidance being shared with investors:

  • Revenue is expected to land between $740 million and $770 million, which represents growth of 25% to 30%.
  • Operating margin is expected to come in between 28% to 30%, which represents a continued expansion from the 26.5% margin that was reported in fiscal 2018.

In summary, Abiomed capped off fiscal 2018 with record results and is poised to continue posting meaningful growth from here.

Minogue ended his prepared remarks on the call with investors by summarizing the state of the business today:

In closing, we enter fiscal 2019 with purpose and confidence in our mission to recover hearts and save lives. We finished the year achieving records on nearly every clinical and business metric, and fortified our leadership position with expanded distribution, training facilities, manufacturing capacity, 317 patents, 311 patents pending, and $400 million in cash. Fiscal 2019 is positioned to be another outstanding year, and we appreciate the investment from our shareholders.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ABIOMED, Inc. Stock Quote
$255.32 (2.69%) $6.70

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.